Compare FDMT & NOAH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FDMT | NOAH |
|---|---|---|
| Founded | 2013 | 2005 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 695.3M | 653.4M |
| IPO Year | 2019 | 2010 |
| Metric | FDMT | NOAH |
|---|---|---|
| Price | $10.38 | $8.67 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 2 |
| Target Price | ★ $31.71 | $11.00 |
| AVG Volume (30 Days) | ★ 794.2K | 95.1K |
| Earning Date | 05-08-2026 | 05-27-2026 |
| Dividend Yield | N/A | ★ 5.66% |
| EPS Growth | ★ 18.79 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $85,209,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $70.28 | $5.71 |
| P/E Ratio | ★ N/A | $13.29 |
| Revenue Growth | ★ 230194.60 | N/A |
| 52 Week Low | $4.27 | $8.47 |
| 52 Week High | $14.00 | $12.84 |
| Indicator | FDMT | NOAH |
|---|---|---|
| Relative Strength Index (RSI) | 42.01 | 29.50 |
| Support Level | $9.71 | $8.63 |
| Resistance Level | $10.50 | $10.73 |
| Average True Range (ATR) | 0.79 | 0.20 |
| MACD | -0.30 | -0.03 |
| Stochastic Oscillator | 10.76 | 8.82 |
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
Noah Holdings Ltd is a wealth management service provider offering comprehensive advisory services on investment and asset allocation, mainly for Mandarin-speaking high-net-worth (HNW) investors. The company's operating segments are Domestic public securities, Domestic asset management, Domestic insurance, Overseas wealth management, Overseas asset management, Overseas insurance and comprehensive services, and Headquarters. Maximum revenue is generated from its Domestic asset management business, which manages private equity funds, real estate equity funds, and private secondary products. The domestic asset management operations focus on managing primary market exits and cross-border ETF products in the secondary market. Geographically, it derives maximum revenue from Mainland China.